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Abstract
Background & Aims—Distinguishing between eosinophilic esophagitis (EoE), 
gastroesophageal reflux disease (GERD), and proton pump inhibitor-responsive esophageal 
eosinophilia (PPI-REE) is challenging. We assessed whether immunohistochemical analysis of 
esophageal tissues for major basic protein (MBP), eotaxin3, and tryptase can be used in diagnosis 
of EoE and to differentiate EoE from PPI-REE.
Methods—We conducted a prospective study of 196 consecutive adults who underwent 
outpatient endoscopy at the University of North Carolina from 2009 through 2012. Incident cases 
of EoE were diagnosed per consensus guidelines. Patients with gastroesophageal reflux disease or 
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dysphagia served as controls. PPI-REE was defined as a symptomatic and histologic response to a 
PPI. Immunohistochemistry was performed to quantify MBP, eotaxin3, and tryptase. The 
maximum density of epithelial staining was determined for each assay; levels were compared 
between EoE and control, and then EoE and PPI-REE groups, and receiver operator characteristic 
(ROC) curves were constructed.
Results—Esophageal tissues from patients with EoE (n=50) had a median 951 MBP-positive 
cells/mm2 whereas those from controls (n=123) had a median 2 MBP-positive cells/mm2 (P<.
001). Samples from patients with EoE had a median 155 eotaxin3-positive cells/mm2 and those 
from controls (n=123) had 18 MBP-positive cells/mm2 (P<.001). Samples from patients with EoE 
had a median 249 tryptase-positive cells/mm2 and those from controls (n=123) had 11 tryptase-
positive cells/mm2 (P<.001). Levels of MBP, eotaxin3, tryptase, and the combination of all 3 
identified patients with EoE with area under the ROC curve values of 0.99, 0.94, 0.99, and 1.00. 
Analyses of only samples with eosinophil counts of 10–100 eos/hpf produced similar results. No 
marker distinguished EoE from PPI-REE. Esophageal tissues from patients with PPI-REE (n=23) 
had 987 MBP-positive cells/mm2 (P=.18, compared with controls), 160 eotaxin3-positive 
cells/mm2 (P=.33), and 243 tryptase-positive cells/mm2 (P=.28).
Conclusions—Esophageal tissues from patients with EoE have substantially higher levels of 
MBP, eotaxin3, and tryptase than controls, based in immunohistochemical analysis. Assays for the 
3 markers identify patients with EoE 100% accuracy, but cannot distinguish EoE from PPI-REE.
Keywords
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Introduction
Eosinophilic esophagitis (EoE) is a chronic, allergen/immune-mediated disease defined by 
symptoms of esophageal dysfunction and an esophageal eosinophilic infiltrate of ≥15 
eosinophils per high-power field (eos/hpf), in the absence of competing causes.1, 2 
Distinguishing EoE from GERD is difficult because symptoms and high levels of 
esophageal eosinophilia can be common to both.3, 4 Additionally, proton pump-inhibitor-
responsive esophageal eosinophilia (PPI-REE), a condition where esophageal eosinophilia 
and symptoms respond to a PPI, further complicates the diagnostic algorithm. PPI-REE is 
now recognized as the cause of esophageal eosinophilia in at least 30–40% of patients, and 
because clinical features are similar in EoE and PPI-REE, a PPI trial is required prior to 
diagnosing EoE.2, 5–7
We have previously demonstrated that staining esophageal biopsies for markers of 
inflammation and eosinophil activation can distinguish EoE from GERD.8, 9 Identifying 
epithelial mast cells with tryptase staining provided strong discrimination between the two 
conditions.8 Staining for major basic protein (MBP), an eosinophil granule protein, and 
eotaxin-3, a potent eosinophil chemokine, also had significant value for separating cases of 
EoE from those with GERD.9 However, these studies were retrospective and were 
conducted prior to the recognition of PPI-REE. No prospective data demonstrate the utility 
of these markers for the diagnosis of EoE. Additionally, it is unknown whether staining for 
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inflammatory markers in PPI-REE patients prior to a PPI trial has utility for discriminating 
EoE and PPI-REE
The aims of this study were to assess the utility of MBP, eotaxin-3, and tryptase staining in 
the esophageal epithelium for diagnosis of EoE using EoE cases and non-EoE controls, and 
to determine whether the same set of stains could differentiate EoE cases from patients with 
PPI-REE prior to a PPI trial. We hypothesized that the stains would be discriminative in 
both situations.
Methods
Study design and case definitions
We conducted a prospective study at the University of North Carolina (UNC) from 2009–
2012 enrolling consecutive adults (age 18–80) undergoing outpatient 
esophagogastroduodenoscopy (EGD). Subjects with either dysphagia or GERD symptoms 
(heartburn, regurgitation/vomiting, reflux, dyspepsia) or as an indication for endoscopy were 
enrolled from the two UNC GI procedure units. Exclusion criteria were: a known diagnosis 
of EoE; a non-EoE eosinophilic gastrointestinal disorder; anticoagulation; GI bleeding; 
esophageal varices; esophageal cancer; prior esophageal surgery; comorbidities or medical 
instability precluding enrollment; and inability to read or understand the consent form. 
Details of portions of this study design were previously reported,7 and it was a stated aim of 
this study to assess tissue biomarkers. Subjects provided informed consent, including 
consent for future use of stored specimens, prior to the endoscopy. This allowed all tissue 
analysis (see below) to be batch run for greatest consistency. The study was approved by the 
UNC IRB.
All cases of EoE were incident, and were defined as per consensus guidelines.1, 2 
Specifically, they had at least one typical symptom of esophageal dysfunction (for example 
dysphagia, food impaction, or heartburn); ≥15 eos/hpf on esophageal biopsy after an 8 week 
PPI trial (20–40 mg twice daily of any of the available agents, selected and prescribed at the 
discretion of the clinician); and other causes of esophageal eosinophilia excluded.
Control subjects were those who underwent endoscopy for an indication of either dysphagia 
or GERD symptoms and did not meet clinical or histologic criteria for EoE. Controls could 
have other evidence of inflammation on biopsy (for example, mixed inflammation including 
eosinophils in the setting of erosive esophagitis). All controls were symptomatic, and there 
were no controls with eosinophilia but no symptoms.
Subjects with PPI-REE were defined as having at least one typical symptom of esophageal 
dysfunction; ≥15 eos/hpf on esophageal biopsy; improvement of esophageal eosinophilia to 
<15 eos/hpf after an 8 week PPI trial (same dosing as above); and improvement of 
symptoms by self-report at the time of the repeat endoscopy. For all study subjects, the 
inclusion/exclusion criteria and case definitions remained constant over the course of the 
entire study.
Dellon et al. Page 3






















Clinical and histologic data
Demographics, symptoms, endoscopy indications and findings were recorded using a 
standardized case report form. During endoscopy, we obtained five research-protocol 
esophageal biopsies (two from the proximal, one from the mid, and two from the distal 
esophagus) to maximize EoE diagnostic sensitivity.10 Research-protocol gastric and 
duodenal biopsies were also collected to exclude concomitant eosinophilic gastroenteritis. 
At the discretion of the endoscopist, additional clinical biopsies were taken as indicated.
For histologic analysis, the study pathologists utilized our validated protocol to determine 
eosinophil counts.11 In brief, slides were masked to the study group, digitized, and viewed 
with Aperio ImageScope (Aperio Technologies, Vista, CA). After examination of five 
microscopy fields from each of the five biopsies, the maximum eosinophil density 
(eosinophils/mm2 [eos/mm2]) was determined. In order to compare the eosinophil densities 
to results from other studies, they were converted to eosinophil counts (eos/hpf) for an actual 
hpf size of 0.24 mm2, the most commonly reported field size in the literature and also the 
field size of the microscopes used at UNC.12
Immunohistochemistry
For immunohistochemistry (IHC), the following primary antibodies were used: anti-MBP 
(mouse, clone BMK 13, catalogue #MCA5751, 1:100 dilution, AbD Serotec, Kidlington, 
UK and Raleigh, NC); anti-eotaxin-3 (goat, #500-P156G, 1:100 dilution, PeproTech, Rocky 
Hill, NJ); and anti-mast cell tryptase (mouse, Clone AA1; #M7052, 1:3000 dilution; Dako, 
Carpinteria, CA). Sections (5 microns) were cut from formalin-fixed paraffin-embedded 
tissue corresponding to the location with the highest level of esophageal eosinophilia and 
were masked to study group. IHC staining was carried out using the Bond Autostainer 
(Leica Microsystems Inc., Norwell, MA). Sections were dewaxed (Bond Dewax solution, 
AR9222) and hydrated (Bond Wash solution, AR9590. Antigen retrieval was with pepsin 
(20 mins) for MBP, and with Bond-Epitope Retrieval solution (citrate, pH=6, AR9961) for 
eotaxin-3 and tryptase. Slides were incubated with the primary antibody, incubated with a 
peroxidase-labelled secondary antibody, stained with a diaminobenzidine chromogen, and 
counterstained with hematoxylin. Stained slides were dehydrated and coverslipped. Lung 
and tonsil were used for controls, as per manufacturer recommendations. Positive control 
slides were incubated with primary antibody to confirm the antibody was working as 
expected. Negative controls were stained with antibody diluent and the secondary antibody 
to assess background staining. These positive and negative controls used tissue expected to 
stain for the targeted antigen. Negative control tissue not expected to stain for the targeted 
antigen was used for stain optimization and control.
Stained slides were analyzed after being scanned, digitized, and viewed, similar to how 
eosinophil counts were determined and in accordance with our previously published 
protocols.8, 9, 13 The maximum density of positively staining cells (cells/mm2) in the 
esophageal epithelial layer for each antibody of interest was quantified in five microscopy 
fields using the Aperio Positive Pixel Count Algorithm, version 9.1.
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Statistical analysis was performed using Stata version 9 (Statacorp, College Station, TX). 
Bivariate analysis was performed with Chi-square for categorical variables, and t-tests, 
Wilcoxon Rank-sum, or Wilcoxon Signed-rank tests for continuous variables as appropriate. 
Receiver operating characteristic (ROC) curves were constructed and area under the curve 
(AUC) was calculated using EoE case status as defined by the consensus diagnostic 
guidelines as the gold standard.1, 2
For the first part of the analysis, ICH staining in the EoE cases (using samples from the post-
PPI trial endoscopy) was compared to non-EoE controls. The AUC was calculated and 
compared for five different models predicting EoE case status: eosinophil count alone; MBP 
staining alone; eotaxin-3 staining alone; tryptase staining along; and a combined model 
containing MBP, eotaxin-3, tryptase staining, but no other clinical, endoscopic, or histologic 
features. For each stain we also determined the cut-point for cell density (cells/mm2) that 
maximized the sensitivity and specificity for EoE diagnosis, and calculated the sensitivity, 
specificity, and positive and negative likelihood ratios (LR). This analysis was repeated for 
pairs of stains (MBP/eotaxin-3; MBP/tryptase; and eotaxin-3/tryptase). Given that the 
majority of controls had no esophageal eosinophilia, we performed sensitivity analyses on 
subgroups of patients presenting diagnostic dilemmas. We first limited the study population 
to those with >10 but <100 eos/hpf, and then repeated the analysis with those with >10 but 
<30 eos/hpf. We also performed a subanalysis on the controls with definitive erosive reflux 
(symptoms of heartburn with erosive esophagitis). ROC curves were constructed for these 
sub-populations, and the AUC, sensitivity, specificity, and positive and negative LRs were 
calculated.
For the second part of the analysis, IHC staining in the EoE cases was compared to subjects 
with PPI-REE. ROC curves were constructed and AUCs were calculated. We compared the 
pre-PPI biopsies of PPI-REE patients to both the post-PPI biopsies of EoE patients and to 
the pre-PPI biopsies of EoE patients (in the subset of EoE patients for whom pre-PPI tissue 
was available). Additionally, we compared the pre-PPI biopsies of EoE patients to their 
matched post-PPI biopsies, to understand the impact of PPI therapy on these markers in 
EoE. Similarly, we compared the pre-PPI biopsies of PPI-REE patients to their matched 
post-PPI biopsies, to understand the impact of PPI therapy on these markers in PPI-REE.
Results
Characteristics of the study population
A total of 196 subjects had available tissue analyzed for this study, 50 with EoE, 23 with 
PPI-REE, and 123 non-EoE controls. EoE cases were a mean of 36 years, 62% were male, 
94% were White, 95% had dysphagia, and the average maximum eosinophil count was 120 
eos/hpf (Table 1). Subjects with PPI-REE were a mean of 48 years, 87% were male, 87% 
were white, and 96% had dysphagia. The pre-PPI average maximum eosinophil count was 
65 eos/hpf, which decreased to 8 eos/hpf after PPI. The controls were a mean of 52 years, 
41% were male, 76% were White, and 58% had dysphagia.
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Utility of MBP, eotaxin-3, and tryptase for distinguishing EoE cases from controls
Staining for MBP, eotaxin-3, and tryptase was qualitatively different between EoE cases and 
controls (Figure 1). Quantitatively, staining levels were markedly higher in those with EoE 
compared to the controls (Figure 2). For MBP, EoE patients had a median of 951 cells/mm2 
(IQR: 322-1849) and controls had 2 (0.4–6) (p<0.001). For eotaxin-3, the values were 155 
(63-783) and 18 (10–31), respectively (p<0.001). For tryptase, the values were 249 (163–
378) and 11 (7–19), respectively (p<0.001).
Analysis of operating characteristics showed these stains had excellent utility for diagnosis 
of EoE. The area under the ROC curves (AUC) for distinguishing EoE from controls were 
0.99, 0.94, and 0.99, for MBP, eotaxin-3, and tryptase, respectively (Table 2). The AUC 
using the eosinophil count alone was 0.992, and the AUC for the combination of all three 
stains was 1.00. The sensitivity and specificity of using the three stains in combination for 
diagnosis of EoE in the absence of eosinophil count or other clinical information were 100% 
and 100%, respectively. When analyzing sets of two stains, for the pair of MBP/eotaxin-3, 
the AUC was 0.98, with a sensitive and specificity of 97% and 94%, respectively. For the 
pair of MBP/tryptase, the AUC was 1.00 with sensitivity and specificity of 100% and 100%. 
For the pair of eotaxin-3/tryptase, the AUC was 0.99, with sensitivity and specificity of 
100% and 99%.
When analysis was restricted to cases (n=26) and controls (n=12) with eosinophil counts 
>10 and <100 eos/hpf, similar results held (Table 2). The AUCs were 0.89, 0.90, and 0.99 
for MBP, eotaxin-3, and tryptase, respectively. The AUC for the eosinophil count alone was 
0.843, while the AUC for the combination of all three stains was 1.00 (Figure 3). In this 
analysis, seven of 12 controls (58%) would have been misclassified as EoE using the 
eosinophil count alone, while none would be misclassified using the three stains. For the 
combination of three stains, the sensitivity and specificity were again 100% and 100%. The 
data were also similar when the analysis was further restricted to cases (n = 6) and controls 
(n = 10) with eosinophil counts >10 and <30 eos/hpf, and to the comparison of all cases to 
controls with erosive reflux (n =13). For both of these sub-groups, the AUC was 1.00 for the 
combination of all three stains (data not shown).
Utility of MBP, eotaxin-3, and tryptase for distinguishing EoE cases from PPI-REE cases
In contrast to the analysis between cases of EoE and controls, there were not clear 
qualitative differences between EoE patients and PPI-REE (Figure 1). Quantitatively, 
staining levels for all three markers were also similar (Figure 2). Compared with the EoE 
staining results noted above, PPI-REE patients had a median of 987 cells/mm2 (IQR: 655–
1917) for MBP (p=0.18), 160 (53–334) for eotaxin-3 (p=0.33), and 243 (163–280) for 
tryptase (p=0.28).
Analysis of the operating characteristics showed these stains did not distinguish between 
confirmed EoE cases and PPI-REE subjects before they had a PPI trial. The AUCs were 
0.60, 0.58, 0.58, and 0.72 for MBP, eotaxin-3, tryptase, and the combination of all three 
stains, respectively.
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A total of 21 baseline (pre-PPI) EoE samples were available for analysis, and there were no 
significant differences in staining patterns between EoE and PPI-REE. The baseline median 
cell counts for the EoE group prior to PPI treatment were 1581 cells/mm2 (IQR: 991–2387) 
for MBP, 266 (162–1092) for eotaxin-3, and 244 (159–348) for tryptase (p=0.37, 0.06, and 
0.70, respectively, compared to the PPI-REE subjects, and p=0.35, 0.69, and 0.91, 
respectively compared to paired post-PPI EoE samples). The stains showed no utility for 
distinguishing EoE and PPI-REE, with AUCs of 0.58, 0.69, 0.54, and 0.67 for MBP, 
eotaxin-3, tryptase, and the combination of all three stains.
The analysis of the post-PPI samples in the PPI-REE group showed marked decreases in the 
levels of staining after the PPI trial. The post-PPI treatment median cell counts were 22 
cells/mm2 (IQR 10–67) for MBP, 21 (11–33) for eotaxin-3, and 56 (28–116) for tryptase 
(p<0.001, p=0.001, and p<0.001, respectively, compared to the paired pre-PPI PPI-REE 
samples).
Discussion
We conducted a prospective study to determine whether staining the esophageal epithelium 
for markers previously demonstrated to be associated with EoE, MBP, eotaxin-3, and 
tryptase, would distinguish EoE cases from non-EoE controls with GERD or dysphagia. We 
additionally sought to define whether these stains could differentiate EoE from PPI-REE. 
Our results confirmed our hypothesis that these stains distinguished EoE from controls. In 
fact, when the three stains were used in combination, and in the absence of any clinical, 
endoscopic, or histologic data, they predicted EoE case status with perfect accuracy. 
Moreover, when we limited the analysis to the subpopulation with intermediate levels of 
esophageal eosinophilia, the group in which there is most often a diagnostic dilemma, the 
combination of stains also performed perfectly.
In contrast, we found that these stains did not have utility for separating EoE from PPI-REE, 
as both sets of subjects had similarly high staining levels. While this was counter to our 
hypothesis, it does raise the intriguing question of whether EoE and PPI-REE may share 
some common pathogenic basis.
The three tissue biomarkers used in this study were selected based on their role in the 
pathogenesis of EoE, that they were unlikely to be increased in GERD, and our previous 
work with these makers.8, 9, 14–22 Specifically, tissue cytokine levels and expression of 
eotaxin-3 are elevated in EoE.14–17 MBP has been used to localize eosinophils and 
characterize degranulation,20, 22 and MBP staining and degranulation is increased in EoE as 
compared to GERD.9, 19, 21, 22 Mast cell-specific genes have been shown to be upregulated 
in EoE,16, 23 and higher levels of mast cells have been reported in EoE.8, 17, 19, 21, 24, 25
Because the esophageal eosinophil count alone does not distinguish EoE and GERD,1, 3, 4 it 
would be desirable to have a set of predictors that are more specific for EoE. IHC is an 
attractive option as it is commercially available, relatively inexpensive, and, with good 
adherence to standardized protocols, reproducible between labs. In two related previous 
studies, we found that MBP, eotaxin-3, and tryptase held promise for diagnosis of EoE.8, 9 
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The results from the present study demonstrate in a prospective cohort the combined utility 
of these markers for the diagnosis of EoE. There is particular clinical utility in patients with 
intermediate eosinophil counts, and in our study 7 of 12 controls (58%) in this intermediate 
range of 10–100 eos/hpf would have been misclassified using the eosinophil count alone, 
whereas none would have been misclassified using the three stains. To optimize the 
usefulness of this panel, we have created an on-line tool that allows the clinician or 
pathologist to enter the results for each of the three stains used in this study and to calculate 
the probability of an EoE diagnosis (https://gicenter.med.unc.edu/cedas/
eoe_calculator.html). In addition, using two of the three stains (ie MBP/tryptase or 
eotaxin-3/tryptase), yields comparable results to staining for all three markers, and could 
potentially reduce cost associated with this test.
Our IHC panel was not able to distinguish EoE from PPI-REE, as both conditions had 
markedly elevated levels of MBP, eotaxin-3, and tryptase. To our knowledge, this is the first 
study to provide immunohistologic data for a group of PPI-REE subjects, and these data 
provocatively suggest that patients with PPI-REE may share some of the same pathogenic 
features as patients with EoE, including elevated levels of mast cells. This may explain the 
difficulty in distinguishing PPI-REE from EoE based on clinical, endoscopic, and routine 
histologic features alone.7 It also may provide a basis for the recent observation that selected 
cytokine levels may be similar.26 Moreover, it is interesting to note that after the PPI trial, 
staining levels markedly decreased, correlating with the reduction in esophageal 
eosinophilia. Further investigation is required to understand the exact relation between EoE 
and PPI-REE and to elucidate pathogenic mechanisms of each.
This study has several limitations. First, it was performed at a single center, so results may 
not be generalizable. However, features of the EoE, PPI-REE, and control populations here 
are comparable to other previously reported populations.6, 10, 27, 28 Second, this study 
enrolled adults, so it is unknown if the data could be applied to children. Our prior studies, 
however, did analyze samples from children and found similar results.8, 9 Third, the number 
of control subjects in our subanalysis with intermediate levels of esophageal eosinophilia 
was relatively small. Fourth, given the widespread use of empiric PPI therapy, only a subset 
of subjects with EoE had PPI-naïve biopsies available for evaluation. While this 
shortcoming is unavoidable in all clinical studies of this type, it is notable that the staining 
levels for the EoE cases were similar both before and after the PPI trial. A related point is 
that pH testing was not performed to attempt to investigate whether reflux might have been 
the etiology of PPI-REE in a subgroup of patients. However, pH testing has not been shown 
to differentiate PPI-REE from EoE or predict PPI response.5, 6 Finally, even with the 
quantitative image analysis strategy used here, IHC can still be a variable technique. We 
mitigated this limitation by using an autostainer and a strict image analysis protocol. 
However, for the diagnostic cut-points determined in this study to hold, clinicians and 
pathologists will need to use a protocol similar to the one presented here.
This study has substantial strengths as well. The study design was prospective, allowing full 
characterization of patients, standardized tissue acquisition and processing protocols, and 
minimizing the likelihood of misclassification. We also used a previously validated 
pathology protocol to determine the eosinophil counts, obtained biopsies to exclude 
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concomitant eosinophilic gastrointestinal disorders, and conducted a sensitivity analysis in 
the subgroup of patients in which these stains would have the highest clinical utility. The 
importance of studies validating preliminary findings is increasingly being recognized, and 
this study was designed to do just that. Moreover, the techniques used are readily available. 
To assist with the incorporation of these techniques into clinical practice, we have created a 
freely accessible EoE predictive calculator (see link above).
In conclusion, this prospective study showed that patients with EoE have substantially 
higher levels of MBP, eotaxin-3, and tryptase staining in the esophageal epithelium 
compared with GERD and dysphagia controls. These results held for the subset of controls 
with esophageal eosinophilia, and the combination of the three stains perfectly predicts EoE 
case status. However, staining levels were similar in EoE and PPI-REE cases. While these 
markers currently do not have value for distinguishing these two conditions prior to the PPI 
trial, the data present some of the first immunopathologic profiling of PPI-REE and raise the 
question of whether EoE and PPI-REE may represent different clinical manifestations of a 
common underlying pathogenic mechanism.
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Representative examples of immunohistochemistry staining. MBP, eotaxin-3, and tryptase 
are demonstrated for a PPI-REE, EoE, and GERD subject.
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Box and whiskers plots of staining in the PPI-REE, EoE, and control groups. The median 
value for each group is noted with the line in the box, the boxes represent the values from 
the 25th percentile to the 75th percentile, and the ends of the whiskers represent the 
maximum and minimum values.
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Receiver operating characteristic (ROC) curves for diagnosis of EoE. The dotted gray line 
represents a test that performs no better than chance (area under the curve [AUC] of 0.5). 
The solid black line is the eosinophil count alone and the dashed dark gray line is for the 
combination of all three stains.
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Table 1
Baseline clinical characteristics of the study groups
PPI-REE (n = 23) EoE (n = 50) Non-EoE controls (n = 123)
Age at diagnosis (mean yrs ± SD) 48.3 ± 11.1 35.9 ± 10.0 51.9 ± 15.3
Male (n, %) 20 (87) 31 (62) 51 (41)
White (n, %) 20 (87) 47 (94) 94 (76)
Symptoms (n, %)
 Dysphagia 22 (96) 36 (95) 62 (58)
 Heartburn 2 (9) 4 (8) 23 (22)
 Abdominal pain/dyspepsia 0 (0) 2 (4) 20 (19)*
 Nausea/vomiting/regurgitation 1 (4) 0 (0) 4 (4)*
Atopic disorders
 Asthma 4 (24) 15 (35) 30 (31)
 Atopic dermatitis 2 (13) 5 (12) 9 (10)
 Allergic rhinitis/sinusitis 6 (35) 31 (72) 55 (57)
 Food allergies 1 (7) 16 (37) 26 (26)
EGD findings (n, %)
 Normal 1 (4) 0 (0) 31 (25)
 Rings 15 (65) 45 (90) 17 (14)
 Stricture 5 (22) 18 (36) 15 (12)
 Narrowing 2 (9) 22 (44) 5 (4)
 Furrows 14 (61) 45 (90) 10 (8)
 Crêpe-paper 1 (4) 5 (10) 0 (0)
 White plaques/exudates 8 (35) 23 (46) 8 (7)
 Decreased vascularity 0 (0) 21 (42) 3 (2)
 Erosive esophagitis 5 (22) 0 (0) 25 (20)
 Schatzki’s ring 5 (22) 2 (4) 9 (7)
 Hiatal hernia 7 (30) 9 (18) 49 (40)
 Dilation performed 8 (35) 13 (26) 29 (24)
Maximum eosinophil count (mean eos/hpf ± SD) 65.2 ± 54.3 119.6 ± 101.6 3.5 ± 10.3
*
Of 20 controls with abdominal pain/dyspepsia, 3 had dysphagia and 2 had nausea or vomiting/regurgitation. Of 4 controls with nausea/vomiting/
regurgitation, 1 had dysphagia.
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